Predictors of Pancreatitis Among Patients with Inflammatory Bowel Disease Treated with Vedolizumab: Observation from a Large Global Safety Database
Abstract Background Patients with inflammatory bowel diseases (IBDs) are at increased risk of pancreatitis. Data from a global safety database (GSD) were queried to identify risk factors for pancreatitis in vedolizumab-treated patients with IBD. Methods Takeda's GSD was retrospectively queried...
Saved in:
Main Authors: | Joe F. Wernicke (Author), Tatsiana Verstak (Author), Tianming Zhang (Author), William Spalding (Author), Laurie Lee (Author), Yue Cheng (Author), Alicia Ademi (Author) |
---|---|
Format: | Book |
Published: |
Adis, Springer Healthcare,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
by: Benjamin Crooks, et al.
Published: (2020) -
A product review of vedolizumab in inflammatory bowel disease
by: Robert Battat, et al.
Published: (2019) -
Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
by: Abdulaziz Saad Alshahrani, et al.
Published: (2023) -
Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab
by: Krupka N, et al.
Published: (2014) -
Impact on the budget of ONLS program of vedolizumab introduction for the treatment of inflammatory bowel disease
by: S. K. Zyryanov, et al.
Published: (2018)